EXERCISE CAPACITY IN PATIENTS WITH CORONARY HEART DISEASE AND PERIPHERAL ARTERY DISEASE, RECEIVING LONG-TERM MILDRONATE THERAPY
Abstract
The paper presents the results of 3 prospective, randomised, double-blind, placebo-controlled trials of patients with coronary heart disease (CHD) and peripheral artery disease (PAD). The aim was to compare veloergometry parameters and skeletal muscle strength in CAD patients, as well as exercise capacity dynamics in PAD patients, during long-term standard therapy with or without additional administration of mildronate (M). According to 3- and 12-month results for CAD patients, M groups demonstrated substantial increases in veloergometry exercise duration and maximal workload, as well as skeletal muscle strength, compared to placebo groups. In PAD patients, 24-week M therapy was associated with substantial increase in absolute claudication distance (ACD) during treadmill test, compared to placebo. Long-term M therapy was effective and safe. Positive effects on ACD were observed even one month after the end of M treatment.
About the Authors
V. Ya. Dzerve
Научный институт кардиологии Латвийского университета
Latvia
Latvia
Yu. M. Pozdnyakov
Московский областной кардиологический центр
Russian Federation
Russian Federation
References
1. Михин В.П., Хлебодаров Ф.Е. Перспективы применения милдроната у больных с сердечно-сосудистой патологией. Российский кардиологический журнал 2010; 84 (4):158-168.
2. D.P. Vivekananthan, E.H. Blackstone, C.E. Pothier et al. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am coll Cardiol, 2003, 42: 831-838.
3. Georgouslias P. Orfanakis A, Demakopoulos N. et al. Abnormal heart rate recovery immediately after treadmill testing: correlation with clinical, exercise testing, and myocardial perfusion parameters. J Nucl Cardiol, 2003, 10 (5): 498-505.
4. Kalviņsh I. Mildronate. The mechanisms of action and perspectives of use. Riga, Grindex, 2002; 36.p]
5. Liepinsh E, Vilskersts R., Loca D., et all. Mildronate, an Inhibitor of Carnitine Biosynthesis, Induces an Increase in Gamma-Butyrobetaine Contents and Cardioprotection in Isolated Rat Heart Infarction. J. Cardiovascular Pharmacology: 2006; 48 (6):314-319.
6. Rowell L.B. Human cardiovascular control. New York, Oxford University Press, 1993, 503 р.
7. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic thearpy of angina pectoris and heart failure. Herz 2002; 27 (7):621-636.
8. Skards J, Dzerve V. A device for determining the contraction strength of the tibial muscle in man VIa.Fiziol Zh SSSR Im I M Sechenova. 1975 Jun; 61(7):1095-7.
9. Stanley W.C., Lopaschuk G.D., Hall J. et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions Cardiovasc. Res.1997; 33 (2):243-257.
10. Tiukinhoy S, Beohar N, Hsie M. Improvement in heart rate recovery after cardiac rehabilitation. J Cardiopulm Rehab, 2003; 23: 84-87[11] Ventura-Clapier, Garnier A., Veksler V. Energy metabolism in heart failure J.Physiol. 2003; 555(1): 1-15.
11. Vitols A, Voita D, Dzerve V. Mildronate improves carotid baroreceptor reflex function in patients with chronic heart failure. Seminars in Cardiovascular Medicine 2007; 13: 6.
Review
For citations:
Dzerve V.Ya., Pozdnyakov Yu.M. EXERCISE CAPACITY IN PATIENTS WITH CORONARY HEART DISEASE AND PERIPHERAL ARTERY DISEASE, RECEIVING LONG-TERM MILDRONATE THERAPY. Russian Journal of Cardiology. 2011;(1):49-55. (In Russ.)
Views:
635
Email this article 